In 2017, Varian calculated that technologies and solutions created by the company were touching some 2.8M (million) cancer patients per year, and established a goal of increasing the number of patients touched to 6M (million) by 2022.
In service of this goal, Varian recently established a new Growth Office to oversee the company’s acquisition integrations, strategic program management, and customer experience initiatives. This new office is being led by Kolleen Kennedy, who has also been named president of Proton Solutions. Chris Toth, former president of Varian’s Global Commercial & Field Operations, succeeded Kennedy as the new president of Varian’s Oncology Systems (VOS) business. Both executives report directly to Dow Wilson, Varian’s president and chief executive officer.
Kennedy, a 21-year veteran of Varian, joined the company In 1997, as marketing manager for radiotherapy delivery systems. She was promoted to manage Oncology Systems product management and marketing in 2001 and added the engineering function in 2002. Between 2005 and 2011, she was the vice president and general manager of the company’s Customer Support Services (CSS) organization. Under her leadership, this organization was rated the #1 service provider among linear accelerator manufacturers every year by IMV, Ltd., an independent healthcare market research firm that analyzes service trends. Kennedy was promoted to president of VOS in October 2011. In this role, she served as the key architect in transforming the organization into geographic structures—establishing a global footprint that enabled Varian to expand successfully in emerging markets around the world. Under her leadership, Varian introduced many new products and services designed to improve the quality of cancer care.
"As president of VOS for the past 7 years, Kolleen has successfully expanded our brand portfolio, integrated 15 acquisitions and improved execution across all geographies in which we operate," said Dow Wilson. "Kolleen has been a consummate leader with a proven track record of producing solid top-line growth while developing people and inspiring teams. I could not be more excited about her appointment to this critical role as we move to our next phase of growth."
Toth, a 19-year Varian veteran, has held many cross-functional roles during his tenure and was most recently president, Global Commercial & Field Operations, where he was responsible for global sales strategy and execution for both the Oncology Systems and the Proton Therapy groups. Under his leadership, orders grew 10 percent in FY17, the results of which will benefit millions of cancer patients for years to come. Previously, Toth served as president of the Americas region where he focused on developing local teams skilled in delivering valuable customer services and differentiated solutions.
"For nearly two decades, Chris has built an impressive track record of strategic, operational and commercial accomplishments," said Dow Wilson. "His strategic thinking, proven ability to deliver results and tremendous passion to create a world without fear of cancer makes him the right leader to help us continue to execute the strategic priorities of the VOS business."